Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
plague (Yersinia pestis) F1 + rV vaccine
- Development stage
- Unknown
- Lead developer
- Lanzhou Institute of Biological Products
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The plague (Yersinia pestis) F1 + rV vaccine is a recombinant protein subunit vaccine candidate designed to provide protection against plague, a severe infectious disease caused by the bacterium *Yersinia pestis*. The vaccine formulation incorporates two key protective antigens: the Fraction 1 (F1) capsular protein and the recombinant V (rV) antigen (also known as LcrV). These antigens are essential for the pathogen's virulence and its ability to evade the host immune response. By inducing the production of specific antibodies against these targets, the vaccine aims to prevent both bubonic and pneumonic forms of the disease. This specific program, developed by the Lanzhou Institute of Biological Products, has undergone Phase 1 clinical evaluation in China to assess its safety, tolerability, and immunogenicity in healthy adults.
- Other names
- recombinant plague vaccine (F1 + rV)Yersinia pestis vaccinerecombinant plague (Yersinia pestis) vaccine containing F1 and rV antigens
02
Targets
F1 antigen (F1 capsular antigen)LcrV (V antigen)T-cell receptor recognizing Yersinia pestis F1 and V antigensBCR-F1/V (B-cell receptor specific for Yersinia pestis F1 and V antigens)
Beyond the preview
Go deeper on plague (Yersinia pestis) F1 + rV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on plague (Yersinia pestis) F1 + rV vaccine.